MISSISSAUGA, Ont., February 22, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that Ms. Jennifer Stewart, an accomplished leader in Canadian business, government and public affairs, has been nominated to serve on its Board of Directors.
If appointed by a majority of shareholders voting at Microbix’s AGM on Wednesday, March 30, 2022, Ms. Stewart will become a member of the Board of Directors and will also be asked to serve as a member of the Human Resources, Compensation & Governance Committee .
Ms. Stewart is the Founder, President and CEO of Syntax Strategic, a leader in advocacy and communications for the public and private sectors. She is known as an expert in the field and is often solicited for comment by national media. In addition, Ms. Stewart was twice named one of the “Top 25 People in the Capital” by Ottawa Life Magazine, one of Ottawa’s “Top Forty Under Forty” by the Ottawa Business Journal and the Ottawa Chamber of Commerce, and was a finalist for Ottawa’s ” Established Female Entrepreneur of the Year.
Ms. Stewart is a graduate in Journalism and Communications from Carleton University (Ottawa, ON) and has been actively involved in business and community affairs in many capacities. Her participations have included President and CEO of the Canadian Independent Petroleum Marketers Association (CIPMA), Board Chair of the Canadian Transportation Alliance, Co-Host and Co-Founder of The Honest Talk Podcast, Chair of the Village of Carp Business Improvement Association, Board Member of the Ottawa’s Youth Services Bureau Foundation, member of the Board of Trustees for the Willis College Women in Technology Scholarship and member of the Leadership Council of the Ottawa Regional Cancer Foundation.
Martin Marino, Independent Chairman of Microbix’s Board of Directors, commented, “I am very pleased to welcome Jennifer on behalf of the directors, management, employees and shareholders of Microbix. Jennifer will bring her skills, connectivity, broad perspectives and expertise to our board level leadership. Their nomination follows a process in which our board evaluated several qualified candidates.”
Commenting on her nomination, Jennifer Stewart said, “I’ve watched Microbix improve public health for Ontario residents and Canadians. If appointed, I look forward to helping Microbix achieve even greater success with its medical devices that support the global diagnostics sector. As a board member, I will be committed to accelerating the pace of value creation in a way that also serves the greater good.”
Upon her appointment, Ms. Stewart will have options to purchase common stock. The options have an exercise price determined by the closing price of Microbix stock on the TSX on the day prior to being granted, a term of five years, and vest after three years.
About Microbix Biosystems
Microbix develops proprietary biological and technological solutions for human health and well-being with approximately 100 skilled employees and revenues of nearly $2.0 million per month. It manufactures a wide range of critical biological materials for the global diagnostics industry, particularly antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical laboratory proficiency testing, enable assay development and validation, or help improve the quality of clinical diagnostics ensure workflows. Microbix antigens enable the antibody testing of over 100 international diagnostic companies, while its QAPs are sold to clinical laboratory accrediting organizations, diagnostic companies and clinical laboratories. Microbix QAPs are now available in over 30 countries and are manufactured by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA, Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG, SDT Molecular distributed Pte Ltd, Seegene Canada Inc. and Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited, US FDA registered, Australian TGA registered, Health Canada licensed and offers CE marked products.
Microbix also leverages its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Viral Transport Medium (DxTM™) to stabilize patient samples for laboratory-based molecular diagnostic testing and Kinlytic® Urokinase, a biological thrombolytic used to treat blood clots. Microbix is traded on the TSX and OTCQB and is headquartered in Mississauga, Ontario, Canada.
This press release contains “forward-looking information” as that term is defined under applicable securities laws. Forward-looking information includes, without limitation, any discussion of Ms. Stewart or her qualifications, her views or those of others, the role or actions of the Board of Directors, Microbix’s business and results, goals or prospects, risks related to financial results and stability, development projects, such as they are mentioned in the company presentation, compliance with legal regulations and permits, sales to domestic and foreign jurisdictions, engineering and construction, production (including control over cost, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising additional capital on acceptable terms, or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this press release and represent the Company’s assessment as of the date of this new press release, and the Company undertakes no obligation to update or revise any forward-looking information.
Please visit www.microbix.com or www.sedar.com for the latest Microbix news and filings.
For more information, please contact Microbix at:
|Cameron Groom, CEO
Adelaide Capital Markets
Torrey Hill’s capital
Copyright © 2022 Microbix Biosystems Inc.
microbiome®Dx™, Kinlytic®and QAPs™ are trademarks of Microbix Biosystems Inc.